

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Beijing Biostar Pharmaceuticals Co., Ltd.**  
**北京華昊中天生物醫藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 2563)**

**NOTICE OF BOARD MEETING**

The board (the “**Board**”) of directors (“**Director(s)**”) of Beijing Biostar Pharmaceuticals Co., Ltd. (the “**Company**”) hereby announces that a meeting of the Board will be held on Monday, 31 March 2025, for the purposes of, among other matters, (i) considering and, if thought fit, approving the consolidated annual results of the Company and its subsidiaries for the year ended 31 December 2024 and its publication; (ii) considering the recommendation for payment of a final dividend, if any; and (iii) transacting any other business.

By order of the Board  
**Beijing Biostar Pharmaceuticals Co., Ltd.**  
北京華昊中天生物醫藥股份有限公司  
**Dr. Tang Li**  
*Chairperson and Executive Director*

Beijing, the PRC, 17 March 2025

*As at the date of this announcement, the Board comprises (i) Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng and Dr. Guan Jin as executive Directors; (ii) Mr. Tang Jin and Mr. Zhu Pai as non-executive Directors; and (iii) Dr. Meng Songdong, Ms. Qi Jingyao and Mr. Ran Dong as independent non-executive Directors.*